DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for torsion dystonia 6 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTorsion dystonia 6 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for torsion dystonia 6 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Torsion dystonia 6 (DYT6) is caused by mutations in the THAP1 gene, identified in 2010 as the second causative gene for primary torsion dystonia after DYT1/TOR1A. This discovery improved mutation detection and understanding of genotype-phenotype correlations. Functional studies on the TOR1A and THAP1 protein products have advanced knowledge of the cellular mechanisms underlying dystonia development. Some healthy non-penetrant individuals carry DYT6 mutations and show subclinical alterations.
The pathophysiology of dystonia involves three proposed mechanisms: a loss of inhibition at different levels of the central nervous system, faulty processing in the lemniscal pathway with abnormal sensory-motor integration, and abnormal maladaptive neuroplasticity triggered by environmental factors such as repetitive training or peripheral nerve injury in susceptible individuals. These mechanisms may be relevant for developing new therapeutic strategies, but no specific drug treatment for DYT6 dystonia is established.
Torsion dystonia is rare, difficult to diagnose, and more difficult to treat. Few controlled studies of therapeutic agents exist due to its rarity. Clinicians have reported that patients' conditions responded or worsened with various pharmacological approaches, but no consolidated treatment protocol exists. Surgical options such as pallidotomy and deep brain stimulation have been explored, driven by successful treatment of drug-induced dystonia in Parkinson's disease, but these are not drug repurposing strategies.
What is still missing are controlled clinical trials for any pharmacological agent in DYT6 dystonia, given the rarity of the condition. Patient stratification by genotype is now possible with THAP1 mutation testing, but no trial has yet used this to test a repurposed drug. Funding for such trials and systematic collection of treatment outcomes remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Opinion on Pharmacotherapy · 2009 · 113 citations
Treatment strategies for dystonia
AbstractIMPORTANCE OF THE FIELD: Dystonia is a neurological syndrome characterized by involuntary twisting movements and unnatural postures. It has many different manifestations and causes, and many different treatment options are available. These options include physical and occupational therapy, oral medications, intramuscular injection of botulinum toxins, and neurosurgical interventions. AREAS COVERED IN THIS REVIEW: In this review, we first summarize the treatment options available, then we provide suggestions from our own experience for how these can be applied in different types of dystonia. In preparing this review article, an extensive literature search was undertaken using PubMed. Only selected references from 1970 to 2008 are cited. WHAT THE READER WILL GAIN: This review is intended to provide the clinician with a practical guide to the treatment of dystonia. TAKE HOME MESSAGE: Treatment of dystonia begins with proper diagnosis and classification, followed by an appropriate search for underlying etiology, and an assessment of the functional impairment associated with the dystonia. The therapeutic approach, which is usually limited to symptomatic therapy, must then be tailored to the individual needs of the patient.
Current Opinion in Neurology · 2008 · 80 citations
Clinical features of dystonia: a pathophysiological revisitation
AbstractPURPOSE OF REVIEW: To elucidate the pathophysiology of some clinical features of dystonic patients and to provide some new insight into the mechanisms underlying task-specific dystonia. RECENT FINDINGS: There are three general lines of work at the present time that may indicate the physiological substrate for dystonia. All three are persuasive and it is not clear whether they are related to each other or whether one is more important than the others. According to the first line of research, a loss of inhibition at different levels of the central nervous system might contribute for the excessive movement seen in dystonia. Another field of research suggests that dystonic patients may have faulty processing within the lemniscal pathway with abnormalities in the sensory-motor integration. Finally, another convincing line of evidence is that in some susceptible individuals, during the acquisition of new motor skills, the mechanisms of neuroplasticity are subtly abnormal. In the presence of such predisposition, several environmental factors, such as repetitive training or peripheral nervous system injury, can trigger an abnormal maladaptive plasticity, which can lead to an overt dystonia. SUMMARY: These findings may be relevant in the development of new therapeutic strategies in dystonia.
Intrathecal baclofen for severe torsion dystonia in a child
AbstractThe successful use of intrathecal baclofen, a structural analogue of gamma-aminobutyric acid, is described in the treatment of a 9-year-old boy with intractable torsion dystonia, not responding to conservative treatment. To our knowledge, this is the first reported case of continuous intrathecal baclofen for hereditary torsion dystonia. This case suggests that a continuous intrathecal infusion of baclofen may facilitate remission of intractable torsion dystonia, and provides a basis for further investigation of the treatment of intractable childhood dystonia.
Advances in the genetics of primary torsion dystonia
AbstractKnowledge about the genetics of primary torsion dystonia (PTD) has been progressing at a very slow pace compared with other movement disorders. For many years, only one causative gene was known, DYT1/TOR1A, yet the recent identification of a second PTD causative gene (DYT6/THAP1), the detection of subclinical alterations caused by mutations in PTD genes in some healthy non-penetrant individuals, and functional studies on TOR1A and THAP1 protein products have significantly improved mutation detection, genotype-phenotype correlates, and our understanding of the cellular mechanisms underlying the development of dystonia.
Expert Opinion on Medical Diagnostics · 2011 · 3 citations
Diagnostic issues in childhood and adult dystonia
AbstractINTRODUCTION: There is a general agreement among movement disorder specialists that the recognition of dystonia may be underestimated. In parallel, the growing interest and the improving knowledge of genetic and physiopathological aspects of dystonias require systematization. AREAS COVERED: This review focuses on the phenomenology and etiology of pediatric and adult dystonias. It is designed to provide practical help for neurologists and neuropediatricians to make appropriate diagnoses and plan the therapeutical management of these disorders. The reader will get a systematization of the main etiological and diagnostic aspects that differentiate child-onset from adult-onset dystonias. The reader will also gain insights into specific treatments or cures. EXPERT OPINION: Because dystonia can vary in clinical presentation and etiology, proper diagnosis and classification of these disorders are important in making therapeutic decisions.
Abstract<h3>To the Editor.—</h3> Torsion dystonia (dystonia muscularum deformans) is a rare condition that is generally difficult to diagnose and more difficult to treat. Our limited understanding of this condition suggests that its mechanism involves abnormalities in one or more neurotransmitter substances in the basal ganglia of the brain. Development of a variety of drugs that modify central neurotransmission has offered considerable therapeutic advance in the treatment of a variety of neurological and psychiatric conditions. Because of the rarity of torsion dystonia, few controlled studies of therapeutic agents have been accomplished in this condition. On the other hand, a variety of clinicians have had experience with one or more patients whose conditions responded or even worsened with one or another pharmacologic approach. I am presently reviewing the pharmacologic treatment of this condition in an attempt to consolidate published and unpublished information regarding potential treatment and mechanisms involved in torsion dystonia. I
Humana Press eBooks · 2003 · 0 citations · open access
Pallidotomy and Pallidal Deep Brain Stimulation for Dystonia
AbstractThe progress that has occurred in our understanding of the pathophysiology of idiopathic dystonia, combined with successful surgical treatment of drug-induced dystonia in Parkinson’s disease (PD), have led to renewed interest in the surgical treatment of dystonia. The purpose of this review is to summarize the current state of surgery for treatment of dystonia with special emphasis on developments during the last five years. For a comprehensive review of this field prior to 1996, see Lang (1).
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
